跳至主要内容
临床试验/EUCTR2021-004865-11-GR
EUCTR2021-004865-11-GR进行中(未招募)1 期

Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazineversus intravenous flecainide alone in the cardioversion of recent onset atrialfibrillation – a randomized, prospective, multicentre, open study, the IV-FLEC study - IV-FLEC

Win Medica Pharmaceuticals S.A.0 个研究点目标入组 210 人开始时间: 2022年3月17日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients can only be included in the study if they meet all of the following
  • 1. Patients aged =18 years
  • 2. Patients with electrocardiographically confirmed AF, with recent onset
  • (self-reported onset of arrhythmia within 48 hours of starting medication
  • reorganization).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 105
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 105

排除标准

  • Patients will be excluded from the study if they meet any of the
  • have the following criteria:
  • 1. Coronary heart disease and / or significant structural heart disease
  • 2. Cardiogenic shock
  • 3. Heart failure, or reduced systolic function left ventricle (ejection fraction <55%)
  • 4. Hypotension (systolic blood pressure <100mmHg)
  • 5. Previous treatment with ranolazine within previous 48 hours.
  • 6. Atrial fibrillation disorder [(2nd degree atrioventricular block, biceps block (RBBB + LAH or RBBB + LPH), or left arm block (LBBB)}, or absent sinus syndrome
  • 7. Hemodynamically intolerant AF
  • 8. Creatinine clearance less than or equal to 30ml / min
  • 9. Moderate or severe hepatic impairment
  • 10. Extended QTc interval (corrected QT> 460ms)
  • 11. Recent treatment with antiarrhythmic drugs category Ic within the previous 24 hours or with amiodarone within the previous 6 months
  • 12. Co-administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, klarithromycin, telithromycin, nefazodone)
  • 13. Known Brugada syndrome
  • 14. Pregnant or breastfeeding women
  • 15. Hypersensitivity to flecainide (flecainide acetate) or to
  • ranolazine or any of the excipients

研究者

发起方
Win Medica Pharmaceuticals S.A.

相似试验